Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.

Key facts

Study ID

NCT00733265

Run by

AstraZeneca

People needed

24

Starts

2007-02-01

Expected to finish

2008-09-01

Last updated by the study team

2010-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients must have severe kidney disease
• Subjects who are matched to the kidney disease patients in terms of weight, age, and sex must have normal kidneys
• All women must be post-menopausal (no longer menstruating) or surgically sterile

You may not qualify if…

• Patients requiring dialysis
• History of allergy to aspirin or clopidogrel
• Have increased bleeding risk (for instance uncontrolled high blood pressure or a recent major injury)
• Recent history of fainting or light-headedness

Where it is running

• Research Site — Phoenix, Arizona, United States
• Research Site — Anaheim, California, United States
• Research Site — Miami, Florida, United States
• Research Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.